Translation of "Hematological malignancies" in German

In patients treated for hematological malignancies, B cell repletion began within 6 months of treatment returning to normal levels between 9 and 12 months after completion of therapy.

The efficacy of RoActemra for the treatment of CRS was assessed in a retrospective analysis of data from clinical trials of CAR T-cell therapies (tisagenlecleucel and axicabtagene ciloleucel) for hematological malignancies.

For patients with hematological malignancies, increases in cardiorespiratory fitness are documented with evidence category B which means that the number of high-quality studies is lower and the results are not consistent.

Sales of MabThera/Rituxan, a monoclonal antibody for hematological malignancies and rheumatoid arthritis, were boosted by physicians prescribing the medicine for the first-line maintenance treatment of follicular lymphoma, a type of non-Hodgkin's lymphoma (NHL).

Likewise, patients with germline mutation-linked ataxia telangiectasia (ataxia telangiectasia mutated, ATM) tend to develop hematological malignancies (19).

About 1.9 million patient exposures with Rituxan/MabThera in hematological malignancies (lymphomas and cancers having their origin in blood cells) have been recorded worldwide since its launch.

The possible association between residence in districts close to high-voltage power lines and the risk of childhood hematological malignancies was investigated in a Japanese study.

The current standard of care in CD20+ hematological malignancies is MabThera/Rituxan (rituximab) in combination with chemotherapy or as a single agent.

Sales of MabThera/Rituxan, a monoclonal antibody for hematological malignancies and rheumatoid arthritis, were boosted by physicians prescribing the medicine for the first-line maintenance treatment of follicular lymphoma, a type of non-Hodgkin’s lymphoma (NHL).

Physical activity improves quality of life which is demonstrated for breast and prostate cancer patients (evidence category B) as well as for patients with hematological malignancies (evidence category C).

It is commonly used in the treatment of a wide range of cancers, including hematological malignancies, many types of carcinoma, and soft tissue sarcomas.

A large proportion of these familial hematological malignancies without identified monogenetic cause appear to have a multifactorial or genetically complex etiology where, besides exogenous factors, numerous genetic risk factors with low or moderate penetrance are involved.

This effect is demonstrated for prostate cancer patients (evidence category A), breast cancer patients (evidence category B) and patients with hematological malignancies with and without stem cell transplantation (evidence category C and B, respectively).

While for Lynch syndrome or familial breast and ovarian cancer diagnostic and therapeutic algorithms have been established for routine clinical use (Box 1 and 2) (1, 2), potential hereditary predisposition to hematological malignancies, such as acute leukemias or myelodysplastic syndromes (MDS), is frequently overlooked, especially in adults (3).

Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors.

The companies will be developing GA101, a humanized anti-CD20 monoclonal antibody engineered to increase both direct- and immune-mediated target cell death, for the potential treatment of hematological malignancies and other oncology-related B-cell disorders such as non-Hodgkin’s lymphoma.

Of 2085 men with cancer, 904 (43%) had hematological malignancies, 680 (33%) testicular cancers and 136 (6.5%) were adolescents.

Hematological malignancies are cancers of the blood and include chronic lymphocytic leukemia (CLL), indolent non-Hodgkin’s lymphoma (NHL) and diffuse large B-cell lymphoma (DLBCL).

Hematological malignancies are cancers of the blood and include chronic lymphocytic leukemia (CLL), indolent non-Hodgkin's lymphoma (NHL) and diffuse large B-cell lymphoma (DLBCL).

In addition, hematological malignancies are associated with a very complex and heterogenic spectrum of various hereditary genetic changes, so-called hereditary mutations.

Among children who lived in districts closer than 300 m to high-voltage power lines a non-significantly increased risk for childhood hematological malignancies was found.

Recently, centrosome aberrations have been described as a possible cause of aneuploidy in hematological malignancies, which could also play a role in MM.

Differential diagnosis include other causes of hypogammaglobulinemia including loss of gammaglobulins via the intestine or urine, hematological malignancies, viral infections or drug-induced loss of B-cell function.

It is commonly used in the treatment of a wide range of cancers, including hematological malignancies (blood cancers, like leukaemia and lymphoma), many types of carcinoma (solid tumours) and soft tissue sarcomas.It is often used in combination chemotherapy as a component of various chemotherapy regimens.

In recent years Bayer has expanded its research focus also to rare bleeding disorders and acute bleeding as well as hemoglobinopathies, hematopoiesis and other hematological diseases including malignancies.

Asunercept is being developed for the treatment of solid tumors and malignant hematological diseases.

It is being developed for the treatment of solid tumors and malignant hematological diseases.

The incidence rate of hematologic malignancies, most notably AML, MDS and B-cell malignancies (including Hodgkin's lymphoma), was 1.31 per 100 person-years for the lenalidomide arms and 0.58 per 100 person-years for the placebo arms (1.02 per 100 person-years for patients exposed to lenalidomide after ASCT and 0.60 per 100 person-years for patients not-exposed to lenalidomide after ASCT).

This included 33 patients with non-melanoma skin cancers, 28 with solid organ cancers, and 6 with hematologic malignancies (4 with lymphomas and 2 with myelodysplastic syndromes).

Secondary CLSs are mostly due to malignant hematological diseases, viral infections, and treatments such as chemotherapies and therapeutic growth factors.

Invasive Candida infections have become common and life threatening complications in patients with leukaemia, cancer, hematologic malignancies and patients with bone marrow transplantation.

The incidence rates per 100 patient-years were 0.73 for non-melanomatous skin cancer, 0.59 for solid malignancies and 0.13 for hematologic malignancies.

Data from a recently completed prospective multicentre phase 2 study including 80 patients, aged 18 to 65 years old, diagnosed with different hematologic malignancies who underwent allo-HCT with an FB (3 days of Busilvex) reduced intensity conditioning regimen became available.

Data from a recently completed prospective multicentre phase 2 study including 80 patients, aged 18 to 65 years old, diagnosed with different hematologic malignancies who underwent allo-HCT with an FB (3 days of busulfan) reduced intensity conditioning regimen became available.

The incidence rate did not increase for malignancies overall, by major type (non-melanomatous skin cancer, solid tumors, and hematologic malignancies), or for individual tumor types in the double blind and open label period compared to the double-blind experience.

Such diseases, for example, include solid timorous diseases, lymphohematopoeitic neoplasia, malign hematological diseases, also in form of a multiple myeloma (or plastocytoma), a histiocytic lymphoma and a burst of CML-blasts.